Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 12/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13148458 | 0.97 | MAP2K1 (0.50) | MAP2K1MAP2K2KDM4EKMT2AMEN1 | |
| SCHEMBL693328 | 0.86 | MAP2K1 (0.69) | MAP2K1MAP2K2 | |
| SCHEMBL694244 | 0.86 | MAP2K1 (0.53) | MAP2K1MAP2K2KMT2AALDH1A1LMNA | |
| SCHEMBL697510 | 0.86 | MAP2K1 (0.53) | MAP2K1KMT2AMEN1ALDH1A1 | |
| SCHEMBL697699 | 0.84 | MAP2K1 (0.52) | MAP2K1MAP2K2KDM4EKMT2AMEN1 | |
| SCHEMBL13148370 | 0.84 | MAP2K1 (0.59) | MAP2K1MAP2K2 | |
| SCHEMBL13148456 | 0.84 | MAP2K1 (0.55) | MAP2K1MAP2K2KDM4EKMT2AMEN1 | |
| SCHEMBL693420 | 0.83 | MAP2K1 (0.50) | MAP2K1MAP2K2KMT2AALDH1A1LMNA | |
| SCHEMBL692982 | 0.81 | ALDH1A1 (0.43) | MAP2K1MAP2K2KDM4EKMT2AMEN1 | |
| SCHEMBL13148371 | 0.79 | MAP2K1 (0.52) | MAP2K1MAP2K2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NRAS, BRAF, MAP3K1 | MAP2K1 48/4885MAP2K2 38/4885KDM4E 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.